High Antigen Expression Can Backfire and Fuel ADC Resistance in Cancer
A counterintuitive mechanism shows that more NECTIN4 antigen on tumor cells can actually blunt antibody-drug conjugate therapy.
Summary
Antibody-drug conjugates, or ADCs, are precision cancer therapies that deliver toxic payloads directly to tumor cells by binding a target antigen on the cell surface. The assumption has long been that more antigen expression means better drug uptake and stronger treatment response. New research challenges this thinking. A commentary in Cancer Cell highlights work by Wang et al. showing that in a resistant subpopulation of tumor cells, higher levels of the NECTIN4 antigen paradoxically reduce how efficiently the drug-antigen complex is pulled inside the cell. Instead of being internalized and releasing its payload where it can do damage, the ADC is shed outside the cell. This finding reframes how oncologists should interpret antigen expression levels when predicting or managing ADC resistance.
Detailed Summary
Antibody-drug conjugates represent one of oncology's most promising advances — engineered molecules that combine the targeting precision of antibodies with the cell-killing power of chemotherapy payloads. They work by binding a specific antigen displayed on tumor cell surfaces, getting pulled inside the cell, and then releasing their toxic cargo. A foundational assumption guiding their development and clinical use has been that tumors expressing higher levels of the target antigen will respond better to treatment.
New research published in Cancer Cell upends this logic in a striking way. A commentary by Charles Dumontet highlights findings from Wang et al. examining resistance mechanisms to enfortumab vedotin, an ADC targeting NECTIN4 used primarily in urothelial cancer. The study identifies a resistant subpopulation of tumor cells characterized not by low antigen expression — the conventional explanation for ADC failure — but by paradoxically high NECTIN4 expression.
The key finding is mechanistic: when NECTIN4 levels rise beyond a threshold in these resistant cells, the internalization process becomes impaired. Rather than being efficiently trafficked into the cell where the payload can be activated, the ADC-antigen complex is released extracellularly. This means the toxic drug never reaches its intracellular target, rendering the treatment ineffective despite abundant antigen availability.
The clinical implications are significant. Tumor profiling that measures antigen expression to predict ADC efficacy may be insufficient or even misleading if internalization dynamics are not also assessed. High antigen expression could serve as a false reassurance of treatment susceptibility.
This work also has broader relevance as the ADC field expands rapidly across cancer types. Understanding resistance at the level of antigen trafficking — not just expression — may become essential for patient selection, combination strategies, and next-generation ADC design. Caveats remain, as this summary is based on the commentary abstract alone.
Key Findings
- High NECTIN4 antigen expression paradoxically reduces ADC internalization in resistant tumor cell subpopulations.
- Resistant cells release the ADC extracellularly rather than internalizing it, preventing intracellular payload delivery.
- ADC resistance can arise independent of low antigen expression, challenging standard resistance frameworks.
- Antigen expression level alone is insufficient to predict ADC therapeutic response.
- Internalization efficiency may need to be evaluated alongside antigen levels in clinical ADC biomarker strategies.
Methodology
This is a commentary piece by Dumontet summarizing findings from a primary research study by Wang et al. published in the same issue of Cancer Cell. The primary study examined NECTIN4 expression and ADC internalization dynamics in resistant tumor cell subpopulations; specific experimental methods are not detailed in the commentary abstract.
Study Limitations
This summary is based on the abstract of a commentary only, not the primary research article or its full data. Experimental details, patient cohort size, cancer type specifics, and statistical methodology from the Wang et al. study cannot be assessed. Generalizability to ADCs targeting antigens other than NECTIN4 is speculative at this stage.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.